drugset / Trial / NCT05789017

Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement

NCT05789017

RandomizedParallel-groupOpen-labelTreatment

Summary

This study has been designed as a 18-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in active IgG4-RD patients with internal organ involvement during maintenance remission period: low dose mycophenolate mofetil group and leflunomide group.

Timeline

Start
2022-07-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule 20 mg
Subject Mycophenolate Mofetil Small molecule 1 g
Subject Mycophenolate Mofetil Small molecule 1.5 g
Background Prednisone Other / unclassified

Indications